{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:48:43Z","timestamp":1762876123801,"version":"build-2065373602"},"reference-count":82,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.lpm.2019.03.016","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T09:56:28Z","timestamp":1572688588000},"page":"338-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"P2","title":["Therapeutic Plasma Exchange in Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy"],"prefix":"10.1016","volume":"48","author":[{"given":"Huy P.","family":"Pham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2019.03.016_bib0415","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/voxs.12113","article-title":"How to approach an apheresis consultation using the American Society for Apheresis guidelines for therapeutic apheresis procedures","volume":"10","author":"Pham","year":"2015","journal-title":"ISBT Science Series"},{"key":"10.1016\/j.lpm.2019.03.016_bib0420","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/jca.10029","article-title":"An approach to evidence-based therapeutic apheresis","volume":"17","author":"McLeod","year":"2002","journal-title":"J Clin Apher"},{"key":"10.1016\/j.lpm.2019.03.016_bib0425","first-page":"149","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"10.1016\/j.lpm.2019.03.016_bib0430","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force","volume":"129","author":"Guyatt","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2019.03.016_bib0435","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2019.03.016_bib0440","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jca.20302","article-title":"Conventional apheresis therapies: a review","volume":"26","author":"Ward","year":"2011","journal-title":"J Clin Apher"},{"key":"10.1016\/j.lpm.2019.03.016_bib0445","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2014","journal-title":"Br J Haematol"},{"year":"2010","author":"McLeod","key":"10.1016\/j.lpm.2019.03.016_bib0450"},{"key":"10.1016\/j.lpm.2019.03.016_bib0455","first-page":"224","article-title":"Prediction of blood volume in normal human adults","volume":"51","author":"Nadler","year":"1962","journal-title":"Surgery"},{"key":"10.1016\/j.lpm.2019.03.016_bib0460","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1111\/trf.13210","article-title":"How we approach a patient with symptoms of leukostasis requiring emergent leukocytapheresis","volume":"55","author":"Pham","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2019.03.016_bib0465","first-page":"346","article-title":"The efficacy of plasma exchange in the removal of plasma components","volume":"104","author":"Derksen","year":"1984","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.lpm.2019.03.016_bib0470","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/asheducation.V2012.1.7.3797920","article-title":"Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines","volume":"2012","author":"Winters","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.lpm.2019.03.016_bib0475","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/vox.12417","article-title":"Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients - an economic evaluation","volume":"111","author":"Okerberg","year":"2016","journal-title":"Vox Sang"},{"key":"10.1016\/j.lpm.2019.03.016_bib0480","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/jca.21392","article-title":"Plasma vs. cryoprecipitate for fibrinogen replacement in therapeutic plasma exchange procedures","volume":"30","author":"Pham","year":"2015","journal-title":"J Clin Apher"},{"key":"10.1016\/j.lpm.2019.03.016_bib0485","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jca.20143","article-title":"Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures","volume":"22","author":"Shemin","year":"2007","journal-title":"J Clin Apher"},{"key":"10.1016\/j.lpm.2019.03.016_bib0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jca.2920090102","article-title":"Complications of therapeutic plasma exchange: a recent assessment","volume":"9","author":"Couriel","year":"1994","journal-title":"J Clin Apher"},{"key":"10.1016\/j.lpm.2019.03.016_bib0495","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1744-9987.2005.00319.x","article-title":"Complications of therapeutic plasma exchange: experience with 4857 treatments","volume":"9","author":"Basic-Jukic","year":"2005","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.lpm.2019.03.016_bib0500","first-page":"CD001798","article-title":"Plasma exchange for Guillain-Barre syndrome","volume":"2","author":"Chevret","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lpm.2019.03.016_bib0505","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.lpm.2019.03.016_bib0510","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/pb.2000.6690","article-title":"Guillain-Barre syndrome: perspectives with infants and children","volume":"7","author":"Jones","year":"2000","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0515","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barre syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2019.03.016_bib0520","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1056\/NEJM195607122550201","article-title":"An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia)","volume":"255","author":"Fisher","year":"1956","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2019.03.016_bib0525","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/brain\/awy232","article-title":"Regional variation of Guillain-Barre syndrome","volume":"141","author":"Doets","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.lpm.2019.03.016_bib0530","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/ana.410330402","article-title":"Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China","volume":"33","author":"McKhann","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0535","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barre syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2019.03.016_bib0540","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(97)12308-X","article-title":"Guillain-Barre syndrome","volume":"352","author":"Hahn","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2019.03.016_bib0545","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJM199511233332102","article-title":"Campylobacter jejuni infection and Guillain-Barre syndrome","volume":"333","author":"Rees","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2019.03.016_bib0550","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMc1609015","article-title":"Zika Virus and the Guillain-Barre Syndrome - Case Series from Seven Countries","volume":"375","author":"Dos Santos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2019.03.016_bib0555","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s13365-018-0621-9","article-title":"Zika virus outbreak in New Caledonia and Guillain-Barre syndrome: a case-control study","volume":"24","author":"Simon","year":"2018","journal-title":"J Neurovirol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0560","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.lpm.2019.03.016_bib0565","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barre syndrome","volume":"27","author":"Asbury","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0570","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.lpm.2019.03.016_bib0575","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00415-016-8380-0","article-title":"Changes in the severity and subtype of Guillain-Barre syndrome admitted to a specialist Neuromedical ICU over a 25 year period","volume":"264","author":"Taylor","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0580","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0585","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/archneur.62.8.1194","article-title":"Supportive care for patients with Guillain-Barre syndrome","volume":"62","author":"Hughes","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0590","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ana.21976","article-title":"Prediction of respiratory insufficiency in Guillain-Barre syndrome","volume":"67","author":"Walgaard","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0595","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","article-title":"Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"61","author":"Hughes","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2019.03.016_bib0600","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1756285609104792","article-title":"Pathogenesis and treatment of immune-mediated neuropathies","volume":"2","author":"Lehmann","year":"2009","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.lpm.2019.03.016_bib0605","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barre syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.lpm.2019.03.016_bib0610","first-page":"CD001446","article-title":"Corticosteroids for Guillain-Barre syndrome","volume":"10","author":"Hughes","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lpm.2019.03.016_bib0615","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ana.410220612","article-title":"French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome","volume":"22","author":"Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement","year":"1987","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0620","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1744-9987.2009.00730.x","article-title":"Guillain-Barre syndrome treated by membrane plasma exchange and\/or immunoadsorption","volume":"13","author":"Marn Pernat","year":"2009","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.lpm.2019.03.016_bib0625","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.braindev.2004.09.013","article-title":"Immunoadsorption therapy for a child with Guillain-Barre syndrome subsequent to Mycoplasma infection: a case study","volume":"27","author":"Arakawa","year":"2005","journal-title":"Brain Dev"},{"key":"10.1016\/j.lpm.2019.03.016_bib0630","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1526-0968.2004.00138.x","article-title":"Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barre syndrome","volume":"8","author":"Okamiya","year":"2004","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.lpm.2019.03.016_bib0635","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1272\/jnms.69.557","article-title":"Plasma immunoadsorption therapy for Guillain-Barre syndrome: critical day for initiation","volume":"69","author":"Takei","year":"2002","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.lpm.2019.03.016_bib0640","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.clineuro.2004.12.019","article-title":"Factors influencing outcome in Guillain-Barre Syndrome: comparison of plasma adsorption against other treatments","volume":"107","author":"Seta","year":"2005","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.lpm.2019.03.016_bib0645","first-page":"225","article-title":"Plasma Exchange\/Sandoglobulin Guillain-Barre Syndrome Trial Group","volume":"349","author":"Randomised trial of plasma exchange intravenous immunoglobulin combined treatments in Guillain-Barre","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2019.03.016_bib0650","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1472-6963-11-101","article-title":"Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barre syndrome","volume":"11","author":"Winters","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.lpm.2019.03.016_bib0655","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/jns5.12051","article-title":"Health-related quality of life in Guillain-Barre syndrome patients: a systematic review","volume":"19","author":"Darweesh","year":"2014","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.lpm.2019.03.016_bib0660","first-page":"777","article-title":"History","volume":"93","author":"Dyck","year":"2018","journal-title":"Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Mayo Clin Proc"},{"key":"10.1016\/j.lpm.2019.03.016_bib0665","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jns.12237","article-title":"ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components","volume":"22","author":"Illa","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.lpm.2019.03.016_bib0670","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/WCO.0000000000000481","article-title":"Chronic inflammatory demyelinating polyneuropathy","volume":"30","author":"Lewis","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0675","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lpm.2019.03.016_bib0680","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0032-1329194","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside","volume":"32","author":"Peltier","year":"2012","journal-title":"Semin Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0685","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1212\/01.wnl.0000167549.09664.b8","article-title":"Distinguishing acute-onset CIDP from Guillain-Barre syndrome with treatment related fluctuations","volume":"65","author":"Ruts","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2019.03.016_bib0690","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(10)70041-7","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition","volume":"9","author":"Vallat","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0695","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1529-8027.2010.00294.x","article-title":"Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"15","author":"Chi","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.lpm.2019.03.016_bib0700","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410300110","article-title":"Serum interleukin-2 concentrations in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis","volume":"30","author":"Hartung","year":"1991","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0705","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1179\/1743132812Y.0000000074","article-title":"Proinflammatory cytokines in serum and cerebrospinal fluid of CIDP patients","volume":"34","author":"Rentzos","year":"2012","journal-title":"Neurol Res"},{"key":"10.1016\/j.lpm.2019.03.016_bib0710","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cyto.2010.05.005","article-title":"The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barre syndrome from chronic inflammatory demyelinating polyneuropathy","volume":"51","author":"Sainaghi","year":"2010","journal-title":"Cytokine"},{"key":"10.1016\/j.lpm.2019.03.016_bib0715","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/WNL.56.5.666","article-title":"Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy","volume":"56","author":"Misawa","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2019.03.016_bib0720","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1024532715775","article-title":"Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy","volume":"23","author":"Press","year":"2003","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0725","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/1531-8249(200006)47:6<765::AID-ANA9>3.0.CO;2-8","article-title":"Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients","volume":"47","author":"Yan","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0730","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archneur.1980.00500590061010","article-title":"Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy","volume":"37","author":"Dalakas","year":"1980","journal-title":"Arch Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0735","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.0000000000000205","article-title":"Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg","volume":"82","author":"Querol","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2019.03.016_bib0740","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1097-4598(200103)24:3<311::AID-MUS1001>3.0.CO;2-A","article-title":"Clinical spectrum of chronic acquired demyelinating polyneuropathies","volume":"24","author":"Saperstein","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lpm.2019.03.016_bib0745","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"Van den Bergh","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0750","first-page":"CD010369","article-title":"Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews","volume":"1","author":"Oaklander","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lpm.2019.03.016_bib0755","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14737175.2017.1340832","article-title":"Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan","volume":"17","author":"Nobile-Orazio","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.lpm.2019.03.016_bib0760","first-page":"CD002062","article-title":"Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"11","author":"Hughes","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lpm.2019.03.016_bib0765","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1586\/ern.09.30","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial","volume":"9","author":"Hughes","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.lpm.2019.03.016_bib0770","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0775","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0780","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jnnp-2013-307515","article-title":"Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP","volume":"86","author":"Nobile-Orazio","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lpm.2019.03.016_bib0785","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"314","author":"Dyck","year":"1986","journal-title":"N Engl J Med"},{"issue":"Pt 4","key":"10.1016\/j.lpm.2019.03.016_bib0790","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.lpm.2019.03.016_bib0795","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0800","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000331011","article-title":"Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment","volume":"66","author":"Galldiks","year":"2011","journal-title":"Eur Neurol"},{"key":"10.1016\/j.lpm.2019.03.016_bib0805","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jca.21546","article-title":"A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy","volume":"32","author":"Lieker","year":"2017","journal-title":"J Clin Apher"},{"key":"10.1016\/j.lpm.2019.03.016_bib0810","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/mus.24707","article-title":"Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy","volume":"52","author":"Dyck","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lpm.2019.03.016_bib0815","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jca.21467","article-title":"More apheresis medicine abstracts should be published into manuscripts for clinical use","volume":"32","author":"Feldman","year":"2017","journal-title":"J Clin Apher"},{"key":"10.1016\/j.lpm.2019.03.016_bib0820","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jca.21405","article-title":"Apheresis research-more abstracts should be published as full manuscripts to provide more evidence for clinical practice guidelines","volume":"31","author":"Pham","year":"2016","journal-title":"J Clin Apher"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219304695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219304695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:06:44Z","timestamp":1760105204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498219304695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":82,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0755498219304695"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2019.03.016","relation":{},"ISSN":["0755-4982"],"issn-type":[{"type":"print","value":"0755-4982"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Plasma Exchange in Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2019.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}